Published in Cancer Weekly, November 6th, 2001
LDP-341, the first investigational drug candidate in a new class of anticancer agents, is a small molecule proteasome inhibitor in clinical development by Millennium as a novel potential therapy for several forms of hematologic and solid tumor cancers.
The multicenter trial, initiated in February 2001, is an open-label study of LDP-341 alone or in combination with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.